PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2021 October; 12(4): e0031. ISSN: 2076-9172Published online 2021 October 25. doi: 10.5041/RMMJ.10450

Table 1.

Summary of Key Findings of Studies Examined in this Review.

Study	Country	Post-vaccination Risk for:			Post-vaccination Follow-up (y)
Study	Country	CD	T1DM	Other	Post-vaccination Follow-up (y)
2017²⁸	Finland	IRR 0.87 (CI 0.65–1.17)	IRR 0.91 (CI 0.69–1.20)	Not examined	4–6
2019³⁰	Finland	Prevalence 0.60% (CI 0.38–0.93) (Placebo group 1.11%)	Prevalence 1.04% (Placebo group 0.97%)	No difference for rheumatoid arthritis^*	11–14
2019³⁹	Australia	NS	IRR 0.85 (CI 0.75–0.97)	Not examined	0–4
2019⁴¹	USA	NS	HR 0.67 (CI 0.54–0.83)	Not examined	0–5
2020⁴²	USA	NS	HR 1.09 (CI 0.87–1.36)	Not examined	1–12
2021²⁹	UK	HR 1.05 (CI 0.86–1.28)	HR 0.89 (CI 0.68–1.19)	Not examined	0–5

^*The study did not have enough patients to examine thyroiditis and inflammatory bowel disease.

CD, celiac disease; CI, confidence intervals; HR, hazard ratio; IRR, incidence rate ratio; NS, not statistically significant; T1DM, type 1 diabetes mellitus; UK, United Kingdom; USA, United States of America.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2021 October; 12(4): e0031. ISSN: 2076-9172

Published online 2021 October 25. doi: 10.5041/RMMJ.10450